Novel chemistry to improve the biostability of organo-astatine bonds in alpha-emitting radiopharmaceutical therapeutics
Novel chemistry to improve the biostability of organo-astatine bonds in alpha-emitting radiopharmaceutical therapeutics
批准号:
10286099
负责人:
Mehran Makvandi
金额:
$32.5万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-07-01 至 2023-04-30
关键词:
AddressAstatineBasic ScienceBiologic DevelopmentBiologicalBiological AssayBloodBoronCarbonCellsChemicalsChemistryClinicalDNADaughterDevelopmentDissociationDrug KineticsDrug TargetingElementsEnsureHalf-LifeHalogensHumanHuman bodyHydrolysisIn VitroIsotopesJournalsKidneyLiverMalignant NeoplasmsMalignant neoplasm of prostateMeasuresMethodsModelingMusNormal tissue morphologyOncogenesOncoproteinsOrganOutpatientsPatientsPharmaceutical PreparationsPharmacologyPositioning AttributeProductionPropertyProsthesisProteinsPublishingRadiationRadiochemistryRadioimmunoconjugateRadioisotopesRadiopharmaceuticalsResistanceRouteScientistShippingSolid NeoplasmSystemTechnologyTestingTherapeuticTimeToxic effectTranslatingTravelTreatment Efficacyanalogbasecancer cellcancer therapycancer typechemical propertychemical stabilityclinical translationdehalogenationdesignhalogenationhigh rewardhigh riskimmune checkpoint blockadeimprovedin vivoinhibitor/antagonistmethod developmentnanobodiesnewsnovelnovel strategiesparticlephysical propertypreventresponsescaffoldsmall moleculetumoruptakevirtualvirtual library
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract/Summary
Of the few -emitting radionuclides that exist, astatine-211 (211At) is one of the most promising -emitting
radionuclides, because its physical and chemical properties are perfectly matched for -emitting
radiopharmaceutical therapeutics (-RPTs) used for treatment of otherwise incurable tumors. However, the in
vivo release of 211At from pharmacological targeting constructs diminishes therapeutic efficacy while increasing
toxicity to normal tissues, and is the single biggest obstacle for realizing the true potential of 211At--RPTs. This
proposal directly addresses the critical unmet need to develop novel chemistry for improving organo-astatine
bond stability to prevent its release in vivo. The carbon-halogen bond strength is inversely related with halogen
size, and as the largest halogen, the bond strength of carbon-astatine (C-At) is the weakest, which makes it
more vulnerable to oxidative dehalogenation in vivo. Currently, most 211At-conjugation methods use C-At bonds
and as a result have poor biostability. Alternatively, using boron-astatine (B-At) bonds, which are stronger than
C-At bonds, is an effective strategy to improve the in vivo stability of 211At--RPTs. Therefore, we propose to
investigate previously unexplored boron hetero-atom ring systems that are uniquely well-suited as pharmacons
to develop biologically stable 211At--RPTs. These ring systems have established halogenation chemistry
adaptable for astatine-substitution at boron or carbon positions in ring systems, each providing unique
properties for enhancing stability and enable orthogonal routes for 211At-radioastatination. In this proposal we
will systematically interrogate the chemistry of astato-substituted boron-heterocycles to develop new methods
for 211At-radioastatination and translate basic science discoveries to application ready technology by
demonstrating “proof of concept” with a biologically stable small molecule 211At--RPT.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金